© ACCESS Newswire
29.01.2026
UTMD
LISTED
NASDAQ
UTMD Reports Year 2025 and Fourth Quarter Financial Performance
News Preview
SALT LAKE CITY, UT / ACCESS Newswire / January 29, 2026 / With some unexpected circumstances in 2025, Utah Medical Products, Inc (UTMD) did not achieve its beginning of year financial projections. Nevertheless the Company retained excellent profit margins, and increased its year-ending cash balances to $85.8 million despite paying $4.0 million in d...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2026
ECIA
LISTED
OTC
Encision Deregisters Common Stock
News Preview
Encision Inc. Announces Decision to Deregister its Common Stock BOULDER, CO / ACCESS Newswire / January 29, 2026 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, announced today that its Board of Di...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2026
RGNT
LISTED
XASE
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
News Preview
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programsGelrinC is set to transform cartilage repair market with off-the-shelf regenerative products HERZLIYA, ISRAEL / ACCESS Newswire / January 29, 2026 / Regentis Biomaterials Ltd., ("Regentis" or the...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
29.01.2026
ATPC
LISTED
OTC
Agape ATP Corporation Receives Nasdaq Notice on Minimum Bid Price Requirement
News Preview
KUALA LUMPUR, MY / ACCESS Newswire / January 29, 2026 / Agape ATP Corporation (NASDAQ:ATPC) ("ATPC" or "the Company") announced that it received a notification letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") on January 27, 2026, indicating that the Company is not in compliance wit...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
29.01.2026
9969
LISTED
HKSE
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
News Preview
Soficitinib demonstrated a favorable safety profile and encouraging efficacy in treating patients with moderate-to-severe AD....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2026
VSEE
LISTED
NASDAQ
VSee and DocBox Announce Strategic Partnership to Launch the First Augmented Intelligence Platform for Virtual ICU
News Preview
Creating a scalable, AI‑native Virtual ICU platform that drives new recurring revenue and enterprise value. SAN JOSE, CALIFORNIA / ACCESS Newswire / January 29, 2026 / VSee Health, Inc. (Nasdaq:VSEE), a leader in enterprise telehealth and AI-powered virtual care, today announced a strategic partnership with DocBox, the first Augmented Intelligence...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2026
ASBP
LISTED
NASDAQ
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin
News Preview
Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to full-scale GMP commercial manufacturing. ESTERO, FLORIDA / ACCESS Newswire / January 29, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a bi...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
ALVO
LISTED
NASDAQ
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
News Preview
REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related t...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
ALVO
LISTED
NASDAQ
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
News Preview
REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes wor...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
TAK
LISTED
NYSE
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
News Preview
Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The co...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
GALD
LISTED
XWSX
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless, authentic results that restore facial balance and improve skin quality, the campaign highlights Restylane’s unique ability to de...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
PPLPHARMA
LISTED
BSE
Piramal Pharma Limited Announces Results for Q3 and 9M FY26
News Preview
MUMBAI, India, Jan. 29, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025.
Consolidated Financial Highlights(in ₹ Crores or as state...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
29.01.2026
PPLPHARMA
LISTED
BSE
Piramal Pharma Limited Announces Results for Q3 and 9M FY26
News Preview
MUMBAI, India, Jan. 29, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025.
Consolidated Financial Highlights(in ₹ Crores or as state...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
PPLPHARMA
LISTED
BSE
Piramal Pharma Limited Announces Results for Q3 and 9M FY26
News Preview
MUMBAI, India, Jan. 29, 2026 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025.
Consolidated Financial Highlights(in ₹ Crores or as stated)Parti...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
SAN
LISTED
EURONEXT
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
News Preview
2025: strong sales and EPS growth.Continued profitable growth expected in 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
News Preview
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
ROG
LISTED
SIX
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
News Preview
Outlook for 2026Roche (SIX: RO, ROG; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.01.2026
IPN
LISTED
EURONEXT
Ipsen nominates Peter Guenter to its Board of Directors
News Preview
PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position....
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
9926
LISTED
HKSE
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
News Preview
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
2269
LISTED
HKSE
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
News Preview
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammator...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
302440
LISTED
KOE
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
News Preview
Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus FamilyNext-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technologySK bioscience will continue to strengthen a Mid- to Long-Term global vaccine strategy centered on universal vaccines for future pandemic prepa...
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2026
TLX
LISTED
ASX
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
News Preview
MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Japanese patients. The patient was dosed at Shona...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2026
NEOG
LISTED
NASDAQ
Neogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution
News Preview
Neogen Corporation (NASDAQ: NEOG) is voluntarily recalling all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
News Preview
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
OILS
LISTED
CSE
Nextleaf Reports Fiscal Year 2025 Financial Performance
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to report its financial results for the Fiscal Year (FY) 2025.For the twelve months ended Septembe...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
PAHC
LISTED
NASDAQ
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results
News Preview
Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 4, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 5, 2026, at 9:00 AM Eastern Time.
Interested parties are invited to listen to the conference call and vie...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
CON
LISTED
NASDAQ
Concentra Announces Preliminary 2025 Financial Results, Provides 2026 Financial Guidance, and Announces Q4 2025 Earnings Call Date
News Preview
Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services by number of locations, today released preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, exceeding its previously issued guidance for...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
CTNM
LISTED
NASDAQ
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on January 26, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Dir...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
CNMD
LISTED
NYSE
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
News Preview
CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025.
Fourth Quarter 2025 Highlights
Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency.
Domestic revenue increased 1.4% year-over-year.
International revenue increased 17...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
GDRX
LISTED
NASDAQ
GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
News Preview
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following m...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
CRTX
LISTED
NASDAQ
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
PSNL
LISTED
NASDAQ
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT.
About Personalis, Inc.
At Personalis,...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
STE
LISTED
NYSE
STERIS Announces Dividend of $0.63 per share
News Preview
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
AGE
LISTED
XASE
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
News Preview
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program -...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
SENS
LISTED
XASE
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Dig...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
AMRX
LISTED
NASDAQ
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
News Preview
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
CBUS
LISTED
NASDAQ
Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock
News Preview
SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value $0.0001 per share (“Class A Common Stock”), in an underwritt...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
NRIX
LISTED
NASDAQ
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
News Preview
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
OGN
LISTED
NYSE
Organon Completes Divestiture of JADA® System to Laborie
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms.
Indications for Use
The JA...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
GBT
LISTED
EURONEXT
Guerbet: Karim Boussebaa appointed Chief Executive Officer
News Preview
Karim Boussebaa Appointed Chief Executive Officer of Guerbet...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
SNOA
LISTED
NASDAQ
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
News Preview
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal hea...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
NHI
LISTED
NYSE
NHI Announces Fourth Quarter 2025 Earnings Release and Conference Call Dates
News Preview
MURFREESBORO, TN / ACCESS Newswire / January 28, 2026 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the fourth quarter ended December 31, 2025. NHI plans to issue its earnings release after the market closes on Thursday, February 26, 2026, and will host a conference call on the following day, Frid...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
KDEV
LISTED
STO
Karolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures AB
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
VYND
LISTED
OTC
Vynleads Unveils “Done With” Lifestyle Blueprint™ Technology Platform; Readies App Launch
News Preview
Vynleads (OTCQB: VYND), a next-gen technology wellness company pioneering lifestyle-first programs for chronic, behavior-linked conditions, today introduced Done With (DWX), a scalable platform vision built to bring structure to the daily realities of chronic, habit-influenced conditions. DWX is designed to replace overwhelm with clarity through c...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
GDTC
LISTED
NASDAQ
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
News Preview
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, inc...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
DTC
LISTED
CSE
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
News Preview
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as par...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
CPH
LISTED
TSX
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)
News Preview
MISSISSAUGA, ON, Jan. 28, 2026 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™ (Spinosad), for the treatment of head lice and scabies.
Natroba™ (Spinosad) is widely recognized as one of the most eff...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
ABBV
LISTED
EURONEXT
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
News Preview
- Nine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluronic acid-based fillers and an innovative filler with biostimulatory properties- Pooled Phase 3 efficacy, safety and patient satisfaction data for Tren...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
MDLN
LISTED
NASDAQ
Medline to report fourth quarter and full year 2025 results on February 25, 2026
News Preview
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference c...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
IZO
LISTED
CSE
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
News Preview
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of b...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
HRAL
LISTED
OTC
Hear At Last Holdings Inc (HRAL) and GG&C Collaborate to Present New Housing Model to Jamaican Government
News Preview
Miami, Florida--(Newsfile Corp. - January 28, 2026) - Hear At Last (OTCID: HRAL) on January 27/26 in collaboration with GG&C, is proud to announce the successful delivery of a comprehensive housing model for presentation to the Jamaican Government. This innovative model is designed to provide a framework for addressing the nation's housing need...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
NTRA
LISTED
NASDAQ
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera’s Prospera Heart test can replace routine invasive biopsies for rejection monitoring in heart transplant recipients.
Positive results would...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
SPRB
LISTED
OTC
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
News Preview
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfil...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
News Preview
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 328,802 shares of common stock at a purchase price o...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
MCK
LISTED
NYSE
McKesson Corporation Declares Quarterly Dividend
News Preview
The Board of Directors of McKesson Corporation (NYSE: MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing hea...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
RGNX
LISTED
NASDAQ
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
News Preview
ROCKVILLE, Md., Jan. 28, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CN...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
ODYS
LISTED
NASDAQ
Odysight.ai Receives Two Pilot Orders from a Major Defense Customer
News Preview
OMER, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a developer of AI-based monitoring and Predictive Maintenance solutions, announced today that it has received two pilot orders from a major defense customer for monitoring applications on aerial platforms....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
AIAI
LISTED
CSE
NetraMark Closes First Tranche of Private Placement
News Preview
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that further to its press release on January...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
SXTP
LISTED
NASDAQ
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
News Preview
60 Degrees Pharma licenses FSU technology to purify castanospermine and begins U.S. regulatory steps for non-Rx Australian Chestnut Extract....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
